Posted On: 11/16/2015 9:44 AM
Tokai ARMOR3– A study of investigational drug for prostate cancer
1. Male age 18 or over
2. Carrier of the AR-V7 splice variant
3. Meet PSA criteria
Sponsored by: Tokai
Length of Study: 2 years
Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.
Research Department (315) 478-4185, option 7
Our Investigator for this study is Christopher Pieczonka, M.D.